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Mesalamine-containing products are often a first-line treatment for ulcerative colitis. Severe adverse reactions to these products,
including cardiovascular toxicity, are rarely seen in pediatric patients. We present a case of a 16-year-old boy with ulcerative colitis
treated with Asacol, a mesalamine-containing product, who developed sudden onset chest pain after four weeks on therapy. Serial
electrocardiograms showed nonspecific ST segment changes, an echocardiogram showed mildly decreased left ventricular systolic
function with mild to moderate left ventricular dilation and coronary ectasia, and his troponins were elevated. Following Asacol
discontinuation, his chest pain resolved, troponins were trending towards normal, left ventricular systolic function normalized,
and coronary ectasia improved within 24 hours suggesting an Asacol-associated severe drug reaction. Mesalamine-induced
cardiovascular toxicity, although rare, may represent a life-threatening disorder. Therefore, every patient presenting with acute
chest pain should receive a workup to rule out this rare drug-induced disorder.

1. Introduction
Mesalamine-(5-aminosalicylic acid) containing products are
a well-known treatment for inflammatory bowel disease,
often as first line. Mesalamine’s mechanism of action is not
completely understood, but seems to reduce colonic inflammation topically by inhibiting the cyclooxygenase pathway and the γ-form of peroxisomal proliferator-activated
receptors (PPAR-γ) signaling pathway. Adverse reactions
to mesalamine are uncommon and include mostly gastrointestinal upset and headaches [1]. Rare drug reactions
to mesalamine have been described in the literature and
include pancreatitis, blood dyscrasias, cardiovascular problems, and interstitial nephritis [2]. Although rare, pericarditis, myocarditis, vasculitis, and left ventricular dysfunction
have been described with mesalamine therapy [3–8]. We
present a case of myocarditis with coronary vasculitis as a
reaction to a mesalamine product, Asacol.

2. Case Presentation
This is a case of a 16-year-old Hispanic male without significant past medical history admitted for evaluation follow-

ing 3-month history of abdominal pain and bloody diarrhea.
Outpatient pediatric gastroenterology evaluation was negative for infectious causes, and due to ongoing symptoms,
he was admitted for further evaluation and treatment.
Colonoscopy performed on admission showed pancolitis
with friable tissue, and biopsies were taken confirming
ulcerative colitis (UC) as the diagnosis. He was started on
methylprednisolone 0.5 mg/kg/dose twice a day and Asacol
400 mg three times a day (30 mg/kg/day). His symptoms
persisted, and on hospital day number four his Asacol dose
was increased to 800 mg three times per day (60 mg/kg/day).
His abdominal pain and bloody diarrhea started to improve
on the new regimen up until hospital day nine when he
developed worsening of symptoms with an acute episode of
bright red blood per rectum. At that point, Azathioprine
4 mg/kg/day was added and the patient was started on
total parenteral nutrition. On hospital day number ten,
he developed a right upper arm superficial thrombosis with superimposed methicillin-sensitive Staphylococcus
thrombophlebitis. Hematology was involved, and he was
started on anticoagulation therapy with low-molecularweight heparin (LMWH) and cefazolin. A hypercoagulable
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Figure 1: Electrocardiogram on day of chest pain onset: sinus tachycardia with no ST segment changes.

V

1 L 6.26 mm

V

2 L 5.16 mm
1 L 5.13 mm

5

5
1

1

2

10

10

94
HR

95
HR
(a)

(b)

Figure 2: Coronary artery ectasia. Right coronary artery diameter measuring 6 mm (a) and left coronary artery diameter measuring 5 mm
(b).

workup, including prothrombin 2021A, factor 5 Leiden
mutation, homocysteine, anticardiolipin antibody, protein
C, protein S, lupus anticoagulant, and Antithrombin III,
was obtained and resulted negative. On hospital day eleven,
he was noted to have intermittent systemic hypertension.
Pediatric nephrology was consulted, and a renal ultrasound
was noted to be normal without renal artery thrombosis
or stenosis. His renal function was within normal limits,
and he was started on nifedipine as needed for systolic
blood pressure greater than 150 mmHg. His elevated blood
pressure was thought to be secondary to steroids. Over the
course of the hospitalization, his platelets began to drop and
on hospital day number fifteen he had a large episode of
hematochezia and some epixtasis. At that point, the LMWH
was stopped and he received packed red blood cells and
platelet transfusions. Due to persistent thrombocytopenia
with poor response to platelet transfusion, he underwent

a bone marrow aspirate that showed cellular marrow with
active hematopoiesis. He was diagnosed with idiopathic
thrombocytopenic purpura (ITP) with positive antiplatelets
antibodies and was treated with intravenous immunoglobulin (IVIG), 1 gram/kilogram/day, without major events.
On hospital day number twenty-nine, he developed
acute chest pain described as throbbing pain located in
the middle of his chest without radiation. His physical
exam was unremarkable except for elevated blood pressure
at 152/91 mmHg and tachycardia with heart rate of 109.
His electrocardiogram showed sinus tachycardia without ST
segment changes (Figure 1). His troponin-I was elevated and
peaked at 0.67 ng/mL, and cardiology was consulted.
A transthoracic echocardiogram revealed mild to moderate dilated left ventricle, mild left ventricular systolic dysfunction with an ejection fraction (EF) of 48%, and bilateral
coronary artery ectasia (Figure 2). His right coronary artery
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Table 1: Correlation of symptoms progression and diagnostic data on and oﬀ Asacol.
On Asacol
day 29
Chest pain
0.157 ng/mL
0.447 ng/mL
0.67 ng/mL

Symptoms
Troponin

Oﬀ Asacol
day 1
Chest pain
0.466 ng/L
0.406 ng/mL

EKG

Sinus Tachycardia
With no ST segment
Changes (Figure 1)

ECHO

Mild-moderate
dilated LV
EF at 48%
Dilated coronary
arteries
RCA 6 mm (Z ≥ +4)
LCA 5 mm
(Z = +2).

Oﬀ Asacol
day 2
None
0.341 ng/mL

Oﬀ Asacol
day 3
None
0.148 ng/mL

Oﬀ Asacol
day 7
None
<0.010 ng/mL

Normal sinus
rhythm with
nonspecific ST
changes in inferior
leads (Figure 4)

Normal sinus
rhythm with
nonspecific ST
changes

Normal sinus
rhythm with sinus
arrhythmia and no
ST segment Changes

Normal sinus
rhythm with sinus
arrhythmia and T
wave inversion in
lead III (Figure 5)

Mildly dilated LV

Mildly dilated LV

Mildly dilated LV

Normal LV

EF at 65%

EF at 59%

Proximal dilation of
coronary arteries

Proximal dilation of
coronary arteries
RCA 6.1 mm

EF at 56%
Proximal dilation of
coronary arteries
RCA 4.5 mm
LCA 5 mm
LDA 3.4 mm

EF at 66%
Proximal dilation of
coronary arteries
RCA 3.8 mm
LCA 4.8 mm
LDA 3.6 mm

mild persistent proximal dilation. His EKG showed normal
sinus rhythm with nonspecific ST segments changes. His
troponin-I continued to trend down, and he was discharged
home. He was seen on followup after a week of Asacol
discontinuation, and his electrocardiogram showed normal
sinus rhythm with T wave inversion in lead III (Figure 5).
His echocardiogram showed mildly dilated left ventricle
with an ejection fraction of 66% and mildly improved
proximal dilation of the coronary arteries. His right coronary
artery measured 3.8 mm, and his left main coronary artery
measured 4.8 mm.
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Figure 3: Cardiac enzymes trend on and oﬀ Asacol.

measured 6 mm in diameter, and the left main coronary
artery was 5 mm in diameter. He was noted to have normal
intracardiac anatomy. He was transferred to the pediatric
intensive care unit for close cardiovascular monitoring. A
decision to discontinue Asacol was made on hospital day
thirty, since it was thought to be the most likely etiology
of his symptoms. After Asacol discontinuation, his chest
pain resolved and his troponins were noted to trend towards
normal (Figure 3).
An electrocardiogram on hospital day one oﬀ Asacol
showed normal sinus rhythm with nonspecific ST segment
changes in the inferior leads (Figure 4). A repeated echocardiogram showed improved left ventricular function with an
EF of 59% and improved coronary artery dilation after two
days oﬀ Asacol. An echocardiogram performed three days
following Asacol discontinuation showed mild dilatation of
the left ventricle with normal systolic function (EF 56%)
and improved coronary artery dilation, although there was

3. Discussion
Cardiac complications in patients with inflammatory bowel
disease may represent a rare extraintestinal manifestation
or drug-related side eﬀect [3, 7]. Cardiac manifestations of
ulcerative colitis (UC) are uncommon and include pericarditis, pericardial eﬀusion, and few cases of pericardiac tamponade. UC-associated pericarditis is a diagnosis of exclusion
after metabolic causes, infection, malignancy, and connective
tissue disorders have been ruled out [9]. Mesalamine-(5aminosalicylic acid) induced cardiovascular toxicity, including pericarditis, myocarditis, vasculitis, and left ventricular
dysfunction, is a rare complication that has been described
in the literature [3–8]. Mesalamine’s mechanism of action is
not fully understood and includes inhibition of the cyclooxygenase pathway and therefore decreased prostaglandins
synthesis and inhibition of the PPAR-γ signaling pathway
resulting in decreased activity of nuclear factor κB and as a
consequence decreased inflammation in the colon [3, 10].
The specific mechanism for mesalamine-induced cardiovascular toxicity is not completely understood but is thought to
be a hypersensitivity reaction rather than a cytotoxic eﬀect. A
proposed mechanism is humoral-mediated hypersensitivity
in which antibodies formed against mesalamine cross-react
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Figure 4: Electrocardiogram 6 hours oﬀ Asacol: normal sinus rhythm and nonspecific ST changes.
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Figure 5: Electrocardiogram 7 days oﬀ Asacol: normal sinus rhythm and T wave inversion lead III.

with cardiac tissue causing inflammation [8]. Most cases
of mesalamine-induced cardiovascular toxicity occur 2–
4 weeks after the initial exposure to the drug, although
presentation may be delayed in the setting of concomitant
steroid administration [8]. Resolution of symptoms has
occurred in all reported cases within one week after drug
discontinuation.
In our case, the patient’s onset and resolution of symptoms and signs are similar to those reported in the literature.
Within twenty-four hours after Asacol discontinuation, our
patient had normalized left ventricular function (Table 1),
making mesalamine-induced myocarditis the most likely
diagnosis. Coronary artery ectasia, seen in our patient, has

been previously described in a similar case in the literature
and may represent a vasculitis type inflammation induced
by mesalamine by a mechanism similar to the one described
above. Although improved after Asacol discontinuation,
mild proximal coronary ectasia persisted one week following
Asacol discontinuation. We will continue to follow this
finding for further correlation.
Our patient also received IVIG during his hospital stay
for ITP, and there are several cases of non-ST elevation as well
as ST elevation myocardial infarction described in the adult
literature in patients with prior risk factors for cardiovascular
disease (i.e., hypertension, diabetes, and coronary artery
disease) after a first cycle of IVIG; this is likely secondary to
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hyperviscosity and complement activation causing occlusion
of vessels already narrowed by atherosclerosis [11–13]. Our
patient did not have any risk factor for cardiovascular disease
and his chest pain presented a week after the IVIG infusion.
There are also no reported cases in the pediatric population
making IVIG a very unlikely suspect.
Mesalamine-induced cardiovascular toxicity, although
rare, may represent a life-threatening disorder that requires
immediate discontinuation of the mesalamine-containing
product and adequate supportive treatment. It is suggested
that every patient, on mesalamine, presenting with acute
chest pain, shortness of breath, or any additional cardiovascular concern undergoes an electrocardiogram, cardiac
enzymes, and an echocardiogram to rule out this rare druginduced disorder.
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